American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
-
Am J Health Syst Pharm · Jul 2011
Multicenter Study Comparative StudyAnticoagulation therapy for hospitalized patients: patterns of use, compliance with national guidelines, and performance on quality measures.
The use of anticoagulant therapy for the prevention and treatment of venous thromboembolism (VTE) and acute coronary syndrome (ACS) among hospital inpatients was evaluated. ⋯ Among hospitals in a large national health care system, the most common use of anticoagulants in hospitalized patients was for VTE prevention, followed by ACS and VTE treatment. Enoxaparin and UFH were the most commonly used agents for each indication, and the selection and use of anticoagulants were in compliance with national guidelines in the majority of patients for whom those drugs were prescribed.
-
Am J Health Syst Pharm · Jan 2009
Multicenter StudyDo current antiemetic practices result in positive patient outcomes? Results of a new study.
The problem of perioperative nausea and vomiting (including postoperative and postdischarge nausea and vomiting [PONV/PDNV]) among people undergoing general anesthesia is discussed. ⋯ Increasing the adherence to guidelines and the rational use of prophylaxis based on patient stratification will reduce the incidence of PONV, as will the development of new antiemetic agents with greater efficacies and longer durations of action that can provide extended protection from nausea and vomiting throughout the 72-hour postsurgical period.
-
Am J Health Syst Pharm · Apr 2004
Multicenter Study Comparative Study Clinical Trial Controlled Clinical TrialAntiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide.
The antiemetic effectiveness of ondansetron 8 mg i.v, ondansetron 32 mg i.v, and granisetron 10 microg/kg or 1 mg i.v. as prophylaxis in breast cancer patients regimens was studied. ⋯ In a retrospective multicenter study, granisetron 1 mg or 10 microg/kg and ondansetron 32 mg appeared more effective than ondansetron 8 mg in preventing acute CINV related to cyclophosphamide therapy.
-
Am J Health Syst Pharm · Nov 2003
Multicenter StudyImpact of prophylactic i.v. magnesium on the efficacy of ibutilide for conversion of atrial fibrillation or flutter.
The impact of prophylactic i.v. magnesium on the efficacy of ibutilide for conversion of atrial fibrillation and flutter to normal sinus rhythm was studied. In this multicenter cohort study, all patients in three large, tertiary care centers who received ibutilide for acute chemical conversion of atrial fibrillation or flutter from August 1996 through December 2001 were identified through pharmacy or billing records. Patients who did not receive magnesium before or during ibutilide therapy served as the control group, while those who received magnesium less than two hours before or during ibutilide administration served as the study group. ⋯ The conversion rate of atrial fibrillation or flutter with ibutilide was enhanced by magnesium administration (p = 0.040), and the rate of administration of DCC was reduced (p = 0.045) in patients who received magnesium. There was a nonsignificant reduction in the occurrence of ventricular arrhythmias (p = 0.533). The efficacy of ibutilide was enhanced by concomitant administration with intravenous magnesium.
-
Am J Health Syst Pharm · Mar 1999
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialCost analysis of remifentanil and fentanyl for neurosurgical anesthesia.